Af­ter CRL in 2022, Pfiz­er and OP­KO get FDA nod for pe­di­atric growth hor­mone de­fi­cien­cy med

Pfiz­er and OP­KO Health have fi­nal­ly cleared the reg­u­la­to­ry hur­dle at FDA for their once-week­ly, long-act­ing growth hor­mone de­fi­cien­cy drug Ngen­la, though As­cendis Phar­ma beat …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER